October 27, 2023 – Page 8

First Hawaiian, Inc. Reports Third Quarter 2023 Financial Results and Declares Dividend

Written by Customer Service on October 27, 2023. Posted in Earnings Releases And Operating Results.

HONOLULU, Oct. 27, 2023 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ:FHB), (“First Hawaiian” or the “Company”) today reported financial results for its quarter ended September 30, 2023. “I’m pleased to report that we delivered strong results in the third quarter. Our loan balances were stable, we grew consumer and commercial deposits, and credit quality remained excellent,” said Bob Harrison, Chairman, President, and CEO. “It was during this time that the world saw the devastating impacts of the wildfires on Maui. Our priority during the quarter was to help our customers, colleagues and the community through this tragedy, and we are committed to helping Maui recover and rebuild stronger than ever.” On October 18, 2023, the Company’s Board of Directors declared a quarterly cash dividend of $0.26 per share. The dividend will...

ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on October 27, 2023. Posted in Earnings Releases And Operating Results.

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly dosing regimen from initiation with a competitive efficacy profile. Preparations underway for the advancement of eblasakimab into Phase 3 clinical development in 2024. Topline interim data from the FAST-AA (FArudodstat STudy in Alopecia Areata) Phase 2a study of farudodstat expected in the first quarter of 2024. $40.8 million in cash and cash equivalents as of September 30, 2023; expected runway into the second half of 2024. SAN MATEO, Calif. and SINGAPORE, Oct. 27, 2023 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company...

Amplify ETFs Declares October Income Distributions for its ETFs

Written by Customer Service on October 27, 2023. Posted in Dividend Reports And Estimates.

CHICAGO, Oct. 27, 2023 (GLOBE NEWSWIRE) — Amplify ETFs announces October income distributions for its ETFs. ETF Name Ticker Amount per Share Ex-Date Record Date Payable Date Amplify Cash Flow Dividend Leaders ETF COWS $ 0.03812 10/27/2023 10/30/2023 10/31/2023 Amplify CWP Enhanced Dividend Income ETF DIVO $ 0.13820 10/27/2023 10/30/2023 10/31/2023 Amplify Cash Flow High Income ETF HCOW $ 0.16688 10/27/2023 10/30/2023 10/31/2023 Amplify International Enhanced Dividend Income ETF IDVO $ 0.13235 10/27/2023 10/30/2023 10/31/2023 Amplify Natural Resources Dividend Income ETF NDIV $ 0.13745 10/27/2023 10/30/2023 10/31/2023 Amplify High Income ETF YYY $ 0.12000 10/27/2023 10/30/2023 10/31/2023 About Amplify ETFsAmplify ETFs, sponsored by Amplify Investments, has over $4.3 billion in assets across its suite of ETFs (as...

Hydrocolloids Market Projected to Reach USD 13.30 Billion by 2027 | Extensive 200-Page Research Report

Written by Customer Service on October 27, 2023. Posted in Mergers And Acquisitions.

Key Companies in Hydrocolloids Market are Kerry Group plc (Tralee, Ireland), Koninklijke DSM N.V. (Heerlen, Netherlands), Cargill, Incorporated (Minnesota, United States), Archer-Daniels-Midland Company (Illinois, United States), DuPont de Nemours, Inc. (Delaware, United States) , Ashland Global Holdings Inc. (Delaware, United States), J.M. Huber Corporation (New Jersey, United States), W Hydrocolloids, Inc. (Philippines), Ingredion, Incorporated (Illinois, United States) and Tate & Lyle plc (London, United Kingdom), and more. Hydrocolloids Market Hydrocolloids Market Size Pune, India, Oct. 27, 2023 (GLOBE NEWSWIRE) — The global hydrocolloids market size is expected to experience substantial growth by reaching USD 13.30 billion by 2027 while exhibiting a CAGR of 5.13% between 2020 and 2027. This is attributable to...

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Written by Customer Service on October 27, 2023. Posted in Earnings Releases And Operating Results.

BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (virtual) – Fireside Chat, November 3, 2023, 1:00 p.m. ET Jefferies London Healthcare Conference (London, UK) – Investor meetings, November 14-15, 2023 The webcasted presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 90 days following the presentation. About Monte Rosa Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines...

Stellar Bancorp, Inc. Reports Third Quarter 2023 Results

Written by Customer Service on October 27, 2023. Posted in Earnings Releases And Operating Results.

HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) — Stellar Bancorp, Inc. (the “Company” or “Stellar”) (NYSE: STEL) today reported net income of $30.9 million and diluted earnings per share of $0.58 for the third quarter 2023 compared to net income of $35.2 million and diluted earnings per share of $0.66 for the second quarter 2023. “We are pleased with our results for the third quarter 2023 given the uncertainty of the economic environment. We remain steadfast in our commitment to provide and protect the qualities we think drive shareholder value; balance sheet strength; sound quality; and stable core deposits,” said Robert R. Franklin, Jr., Stellar’s Chief Executive Officer. “We continue our strategy of not fighting the actions of the Federal Reserve as it attempts to slow the economy to tamp down inflation. Raising interest rates is a...

Balchem Corporation Reports Third Quarter Sales of $229.9 Million, with Net Earnings of $29.1 Million, GAAP EPS of $0.90, and Adjusted EPS of $1.04

Written by Customer Service on October 27, 2023. Posted in Earnings Releases And Operating Results.

MONTVALE, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) reported today third quarter net sales of $229.9 million for 2023, compared to net sales of $244.3 million in the prior year quarter. Third quarter net earnings were $29.1 million for 2023, compared to net earnings of $25.2 million for the third quarter 2022. Adjusted net earnings(a) were $33.8 million for the third quarter of 2023, compared to $32.4 million for the third quarter of 2022. Quarterly adjusted EBITDA(a) was $59.9 million, compared to $53.8 million in the prior year quarter. Third Quarter 2023 Financial Highlights: Third quarter net sales were $229.9 million, a decrease of $14.3 million, or 5.9%, compared to the prior year. Record quarterly adjusted EBITDA was $59.9 million, an increase of $6.1 million, or 11.4%, from the prior year. GAAP...

AppTech Payments Corp. Completes Acquisition of FinZeo

Written by Customer Service on October 27, 2023. Posted in Mergers And Acquisitions.

CARLSBAD, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) — AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce between business to business and business to consumer, today announced that it completed its acquisition of Alliance Partners, LLC, owners of FinZeo, a software development company centered around the movement of money, nationally and globally. FinZeo was founded in 2018 and is dedicated to delivering innovative payment and banking technology solutions for businesses of all sizes. By integrating the FinZeo platform, AppTech believes it can augment its technology offerings, furnishing users with cutting-edge tools accessible via online portals or through an API. “This acquisition aligns seamlessly with AppTech’s strategic initiatives, marking our steadfast commitment to investing...

ACM Research Announces Preliminary Unaudited Revenue Range for Third Quarter 2023

Written by Customer Service on October 27, 2023. Posted in Public Companies.

FREMONT, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced wafer-level packaging applications, today announced that its preliminary unaudited revenue for the third quarter of 2023 is expected to be in the range of $165 million to $168 million. Actual unaudited third quarter 2023 results are subject to the completion of ACM’s quarter end closing procedures and review by ACM’s independent registered public accounting firm. ACM will discuss its full financial results for the third quarter of 2023 and its revenue outlook for the remainder of the year on its earnings call on Tuesday, November 7, 2023, at 8 a.m. Eastern Time (9 p.m. China Time). Today’s release of ACM’s third quarter 2023 preliminary unaudited expected revenue...

Microbix QAPs Supporting HPV Testing in Ireland

Written by Customer Service on October 27, 2023. Posted in Public Companies.

Distribution Partner Secures Contract Relating to Cervical Cancer Screening MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state. Microbix’s local distribution partner, The Medical Supply Company of Ireland (“MSC”), has secured a tender-based contract to supply goods and services to support this national-level MDx and HPV-based cervical cancer screening program. The program is being driven by the instrumentation and reagents of the Roche Diagnostics Corporation...

Day: October 27, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice